Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Clinical characteristics and outcomes of severe rhinovirus-associated pneumonia identified by bronchoscopic bronchoalveolar lavage in adults: Comparison with severe influenza virus-associated pneumonia

Sang-Ho Choi\textsuperscript{a,1}, Jin Won Huh\textsuperscript{b,1}, Sang-Bum Hong\textsuperscript{b}, Ju Young Lee\textsuperscript{a}, Sung-Han Kim\textsuperscript{a}, Heungsup Sung\textsuperscript{c}, Kyung-Hyun Do\textsuperscript{d}, Sang-Oh Lee\textsuperscript{a}, Mi-Na Kim\textsuperscript{c}, Jin-Yong Jeong\textsuperscript{a,e}, Chae-Man Lim\textsuperscript{b}, Yang Soo Kim\textsuperscript{a}, Jun Hee Woo\textsuperscript{a}, Younsuck Koh\textsuperscript{b,1}

\textsuperscript{a} Department of Infectious Diseases, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea
\textsuperscript{b} Department of Pulmonary and Critical Care Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea
\textsuperscript{c} Department of Laboratory Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea
\textsuperscript{d} Department of Radiology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea
\textsuperscript{e} Asan Institute for Life Sciences, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea

\section*{A R T I C L E   I N F O}

Article history:
Received 27 August 2014
Received in revised form 4 November 2014
Accepted 7 November 2014

Keywords:
Rhinovirus
Pneumonia
Influenza

\section*{A B S T R A C T}

\textbf{Background:} Rhinoviruses (RVs) may cause pneumonia, but the characteristics of RV-associated pneumonia have not been adequately evaluated.

\textbf{Objective:} We aimed to compare characteristics, complications, and outcomes between severe RV- and influenza virus (IFV)-associated pneumonia in adults.

\textbf{Study design:} We used prospective cohort data of adult patients with severe pneumonia who had been admitted to the medical intensive care unit of a tertiary care hospital over a 4-year period. The clinical features and outcomes of 27 patients with RV-positive bronchoscopic bronchoalveolar lavage (BAL) fluid were compared to those of 51 pneumonia patients with IFV-positive BAL fluid or IFV-positive nasopharyngeal specimens.

\textbf{Results:} Of 356 patients who underwent bronchoscopic BAL and respiratory virus polymerase chain reaction (PCR), RV was the most commonly identified virus (8.1\%) from BAL fluid. Patients with RV-associated pneumonia were more likely to be immunocompromised than patients with IFV-associated pneumonia (81.5\% vs. 33.3\%, p = 0.001). Bacterial co-infection tended to be less common in the RV group (18.5\% vs. 37.3\%, p = 0.09). Although septic shock was less common in the RV group (29.6\% vs. 54.9\%, p = 0.03), other clinical manifestations, laboratory findings, and radiologic patterns were similar between the groups. The 28-day mortality of patients with severe RV- and IFV-associated pneumonia was similarly high (29.6\% vs. 35.3\% respectively, p = 0.61).

\textbf{Conclusions:} Severe RV-associated pneumonia patients were more likely to be immunocompromised and less likely to present septic shock. Overall clinical features were similar and mortalities of both groups were comparably high. Studies of larger cohorts encompassing mild to moderate pneumonia patients are needed.

© 2014 Elsevier B.V. All rights reserved.

\section{1. Background}

RV is a non-enveloped, non-segmented single-strand RNA virus of the genus Enterovirus and the family Picornaviridae \cite{1}. In adults, RVs are a predominant etiology of upper respiratory tract infections, also known as ‘common colds’, and are frequently associated with exacerbation of asthma \cite{2} and COPD \cite{3}. RVs’ ability to reach and infect the lower respiratory tract epithelium has been demonstrated recently \cite{4–7}, and the link between RV and pneumonia has gained recent attention \cite{8–12}. However, the role of RV in the pathogenesis of pneumonia remains controversial.

\textbf{Abbreviations:} RV, rhinovirus; IFV, influenza virus; BAL, bronchoalveolar lavage; PCR, polymerase chain reaction; COPD, chronic obstructive pulmonary disease; ICU, intensive care unit; APACHE, Acute Physiological and Chronic Health Evaluation; SOFA, Sequential Organ Failure Assessment.

* Corresponding author at: Department of Pulmonary and Critical Care Medicine, Asan Medical Center, University of Ulsan College of Medicine, 88, Olympic-ro 43-gil, Songpa-gu, Seoul 138-736, Republic of Korea. Tel: +82 2 3010 3304; fax: +82 2 3010 6970.
E-mail address: yskoh@amc.seoul.kr (Y. Koh).

\textsuperscript{1} These authors contributed equally to this work.

\url{http://dx.doi.org/10.1016/j.jcv.2014.11.010}
1386-6532/© 2014 Elsevier B.V. All rights reserved.
Histopathological examination of lung tissue specimens, including in situ hybridization of RV RNA, would be helpful to establish the role of RVs in pneumonia development. However, such examination is rarely possible in clinical practice. A prior report suggests that RVs infect a small subset of lower airway epithelial cells [7] and activate marked inflammatory responses, rather than directly invade lower airways in the lower respiratory tract epithelium [13–15]. Therefore, RV detection using bronchoalveolar lavage (BAL) fluid specimens from severe pneumonia patients may be an indirect but meaningful indicator for the pathogenic role of RV. However, clinical data using BAL specimens from unselected adult patients with RV-associated pneumonia are scarce [10,16,17], with some studies investigating small subsets of a retrospective series of respiratory virus infection [16,17]. The majority of prior studies using BAL specimens were confined to small groups of hematopoietic stem cell transplant patients [12,18–20], which limits our understanding of RV-associated pneumonia.

IFV is the major cause of severe viral pneumonia in adults during the epidemic season, and clinical features, complications, and outcomes of IFV-associated pneumonia have been well documented. Therefore, comparing RV- and IFV-associated pneumonia may help clinicians understand the clinical characteristics of RV-associated pneumonia.

2. Objectives

The aim of this study was to investigate the clinical and laboratory characteristics, complications, and outcomes of severe RV-associated pneumonia identified by bronchoscopic BAL in adults and to compare them with IFV-associated pneumonia.

3. Study design

3.1. Study design, setting, patient population, and data collection

This study was part of our ongoing prospective observational study regarding severe pneumonia in critically ill adults [21–23]. Since March 2010, all patients ≥16 years of age who were clinically suspected of having severe pneumonia were admitted to a 28-bed medical ICU of the Asan Medical Center, a 2700-bed tertiary care hospital in Seoul, Republic of Korea. Patients were prospectively identified and monitored until the time of discharge or death. The collected data included demographic characteristics, underlying diseases or conditions, symptoms and signs, laboratory test results, radiologic findings, treatment, complications, ICU and hospital lengths of stay, and mortalities. This study was approved by the Asan Medical Center Institutional Review Board. Due to the observational nature of the study, a waiver of the informed consent was allowed.

3.2. Patient selection

The current study included severe pneumonia patients with RV- or IFV-positive respiratory specimens admitted to the medical ICU between March 2010 and February 2014. For the RV group, only BAL fluid RV polymerase chain reaction (PCR)-positive cases were included. The IFV group included both BAL fluid and nasopharyngeal specimen IFV PCR-positive cases. Cases of mixed RV and IFV infection were excluded from the analysis.

3.3. Definitions

Pneumonia was defined and categorized as previously described [24–26]. Severe pneumonia was defined as the need for mechanical ventilation or septic shock at the time of ICU admission [25]. Immuno compromised state was defined as previously described [27].

3.4. Bronchoscopic BAL procedure and microbiological evaluation

BAL procedure and microbiological evaluation of the BAL fluid were performed following a previously described standardized protocol [21–23]. Respiratory virus PCR was performed by multiplex reverse-transcription PCR assay using the Seegene RV 2014 ACE Detection kit (Seegene Inc., Seoul, Korea). This kit simultaneously detects all RV species including RV groups A, B, and C; IFV A and B; adenovirus, parainfluenza virus types 1, 2, 3, and 4; respiratory syncytial virus types A and B; human metapneumovirus; enterovirus; human coronaviruses OC43/HKU1; human coronaviruses 229E/NL63; and bocavirus. The primers were targeted to the 5′-noncoding region and designed to distinguish between RV and enterovirus.

3.5. Statistical analysis

Demographic, clinical, and laboratory parameters were compared between RV patients and IFV patients. Categorical variables were compared by chi-square or Fisher’s exact test, and continuous variables were compared by Student’s t-test or Mann–Whitney U test. P values of <0.05 were considered statistically significant. All analyses were performed using SPSS version 21.0 (SPSS, Chicago, IL).

4. Results

4.1. Study population

Fig. 1 shows the patient selection process and the reasons for exclusion. During the 48 months of the study period, a total of 1232 patients were admitted to the medical ICU with a diagnosis of severe pneumonia (260 with community-acquired pneumonia [CAP], 475 with healthcare-associated pneumonia [HCAP], and 497 with hospital-acquired pneumonia [HAP]). Of these patients, 376 underwent bronchoscopic BAL. Multiplex respiratory virus PCR was performed on the BAL fluid in 356 cases (94.7%). Among them, one or more viruses were identified in the BAL fluid of 105 patients (29.5%, 105/356). RV was the most common virus identified (8.1%, 29/356), followed by parainfluenza virus (6.7%, 24/356), respiratory syncytial virus (6.5%, 25/356), IFV (5.6%, 20/356), human coronavirus (2.2%, 8/356), human metapneumovirus (2.0%, 7/356), and adenovirus (1.1%, 4/356). In addition to 20 IFV-positive cases identified by BAL fluid, 36 IFV-positive cases with severe pneumonia were identified by nasopharyngeal specimen. After excluding the patients who were PCR-positive for both RV and IFV, we included 27 severe RV-associated pneumonia patients and 51 severe IFV-associated pneumonia patients (45 IFV A and 9 IFV B) in our analysis.

4.2. Demographics, underlying diseases/conditions, and category of pneumonia

The demographic, underlying diseases/conditions, and category of pneumonia are summarized in Table 1. The proportion of male patients was higher in the RV group than in the IFV group (77.8% vs. 54.9%, p = 0.047). The median ages of the RV group patients and the IFV group patients were 66.0 years and 62.0 years, respectively. Structural lung disease, hematologic malignancy, and diabetes mellitus were the most common underlying diseases in both groups. Of these, hematologic malignancy was significantly more common in the RV group (40.7% vs. 13.7%, p = 0.007). A greater proportion of RV patients were immunocompromised (81.5% vs. 33.3%, p < 0.001) and current smokers (14.8% vs. 1.9%, p = 0.04). CAP was significantly
more common in the IFV group (11.1% vs. 37.3%, p = 0.02), and HCAP was more common in the RV group (55.6% vs. 31.4%, p = 0.04).

The characteristics of five RV patients who were not immunocompromised are summarized in Table 2. Of these patients, two had underlying COPD. Another two patients were 70 years old and 81 years old, respectively, and neither had remarkable underlying disease, history of hospitalization, or identifiable co-pathogens. The last patient had underlying diabetes mellitus and had undergone recent esophageal surgery. RV was co-identified with respiratory syncytial virus A and *Acinetobacter baumannii* in this patient.

### 4.3. Co-pathogens identified

Table 3 shows the co-pathogens identified with RV and IFV. Twelve of the RV patients (44.4%) and 26 (51.0%) of the IFV patients had one or more other respiratory pathogens identified from either BAL fluid or other specimens. Viral coinfection tended to be more

---

**Table 1**

| Demographics, underlying diseases/conditions, and categories of pneumonia. | Total (n = 78) | Rhinovirus (n = 27) | Influenza virus (n = 51) | p-Value |
|---|---|---|---|---|
| Male sex | 49 (62.8) | 21 (77.8) | 28 (54.9) | 0.047 |
| Age, median (interquartile range) | 65.0 (53.8–71.0) | 66.0 (57.0–70.0) | 62.0 (53.0–73.0) | 0.77 |
| Underlying disease or condition | | | | |
| Structural lung disease | 22 (28.2) | 7 (25.9) | 15 (28.4) | 0.75 |
| Chronic obstructive lung disease | 10 (12.8) | 3 (11.1) | 7 (13.7) | 1.00 |
| Interstitial lung disease | 7 (9.0) | 4 (14.8) | 3 (5.9) | 0.23 |
| Bronchiectasis | 4 (5.1) | 1 (3.7) | 3 (5.9) | 1.00 |
| Destroyed lung due to tuberculosis | 1 (1.3) | 0 | 1 (2.0) | 1.00 |
| Pneumococcosis | 1 (1.3) | 0 | 1 (2.0) | 1.00 |
| Hematologic malignancy | 18 (23.1) | 11 (40.7) | 7 (13.7) | 0.007 |
| Diabetes mellitus | 16 (20.5) | 7 (25.9) | 9 (17.6) | 0.39 |
| Solid cancer | 10 (12.8) | 3 (11.1) | 7 (13.7) | 1.00 |
| End-stage renal disease | 2 (2.6) | 0 | 2 (3.9) | 0.54 |
| Congestive heart failure | 4 (5.1) | 0 | 4 (7.8) | 0.29 |
| Liver cirrhosis | 1 (1.3) | 1 (3.7) | 0 | 0.35 |
| Chronic renal failure | 3 (3.8) | 0 | 3 (5.9) | 0.55 |
| s/p cerebrovascular attack | 1 (1.3) | 0 | 1 (2.0) | 1.00 |
| Solid organ transplantation | 3 (3.8) | 2 (7.4) | 1 (2.0) | 0.27 |
| Hematopoietic stem cell transplantation | 9 (11.5) | 4 (14.8) | 5 (9.8) | 0.71 |
| Immuno compromised state | 39 (50.0) | 22 (81.5) | 17 (33.3) | < 0.001 |
| Receipt of immunosuppressant | 21 (26.9) | 14 (51.9) | 7 (13.7) | < 0.001 |
| Recent chemotherapy | 17 (21.8) | 9 (33.3) | 8 (15.7) | 0.07 |
| Active smoker | 5 (6.2) | 4 (14.8) | 1 (1.9) | 0.04 |
| Ex-smoker | 28 (35.9) | 11 (40.7) | 17 (33.3) | 0.52 |
| Recent surgery (within 1 month) | 3 (3.8) | 2 (7.4) | 1 (2.0) | 0.27 |
| Neutropenia | 8 (10.3) | 5 (18.5) | 3 (5.9) | 0.12 |
| Category of pneumonia | | | | |
| Community-acquired pneumonia | 22 (28.2) | 3 (11.1) | 19 (37.3) | 0.02 |
| Healthcare-associated pneumonia | 31 (39.7) | 15 (55.6) | 16 (31.4) | 0.04 |
| Hospital-acquired pneumonia | 25 (32.1) | 9 (33.3) | 16 (31.4) | 0.86 |

Data are presented as No. (%) unless otherwise stated.

* Some patients had one or more underlying diseases or conditions.

* Defined as one of the following conditions: (i) daily receipt of immunosuppressants, including corticosteroids, (ii) human immunodeficiency virus infection, (iii) solid organ or hematopoietic stem cell transplant recipients, (iv) receipt of chemotherapy for underlying malignancy during the previous 6 months, and (v) underlying immune deficiency disorder.

* Absolute neutrophil count < 500/mm$^3$. 

---

**Fig. 1.** Patients selection process. BAL = bronchoalveolar lavage, IFV = influenza virus, RV = rhinovirus. *includes three RV samples from nasopharyngeal specimens.
Table 2

| Patient No. | Year/ Month | Age | Gender | Underlying disease or condition | Category of pneumonia | Nasopharyngeal rhinovirus PCR | Co-pathogen | CT findings | Outcome (Cause of death) |
|-------------|-------------|-----|--------|---------------------------------|-----------------------|-------------------------------|-------------|-------------|--------------------------|
| 1           | 2010/ April | 73 | male   | COPD                            | CAP                   | Not done                      | None        | Bilateral multifocal ground-glass opacity with interlobular septal thickening | Died at hospital day 9 (pulmonary embolism) |
| 2           | 2010/ June  | 64 | male   | COPD, bronchiectasis            | CAP                   | Negative                      | None        | Bilateral multifocal ground-glass opacity with interlobular septal thickening | Alive |
| 3           | 2010/ July  | 70 | male   | COPD                            | HAP                   | Positive                      | None        | Right-sided lower lung consolidation | Alive |
| 4           | 2010/ August| 81 | male   | COPD, diabetes mellitus, insulin-dependent diabetes | HAP                   | Negative                      | None        | Bilateral multifocal ground-glass opacity with interlobular septal thickening | Died at hospital day 81 (ventilator-associated pneumonia) |
| 5           | 2011/ January | 64 | male   | Diabetes mellitus, insulin-dependent diabetes | HAP                   | Negative                      | None        | Bilateral multifocal ground-glass opacity with interlobular septal thickening | Alive |

4.4. Clinical manifestations, laboratory findings, radiological findings, and seasonality

Clinical, laboratory, and radiologic characteristics are compared in Table 4. Dyspnea, sputum, and fever were the most common symptoms in both groups. Cough tended to be less common in the RV group (66.7% vs. 84.3%, p = 0.07). Septic shock at the time of ICU admission was significantly more common in the IFV group (29.6% vs. 54.9%, p = 0.03). However, the rate of mechanical ventilation and severity index, measured by APACHE II score and SOFA score, did not differ between the two groups. Bacterial coinfection was significantly associated with septic shock (with bacterial coinfection, 66.7% [16/24] vs. without bacterial coinfection, 37.0% [20/54], p = 0.02). When the analysis was confined to patients without coinfection, the incidence of septic shock at ICU admission was similar between the two groups (RV group, 40.0% [6/15] vs. IFV group, 44.4% [11/25], p = 0.80).

Peripheral white blood cell counts (WBC), platelet counts, serum C-reactive protein levels, and procalcitonin levels were not significantly different between the two groups. Median total WBC counts and differential counts in the BAL fluid were not significantly different between the groups.

The radiologic patterns of pneumonia were mostly bilateral and often showed diffuse involvement in both groups. Differences in radiologic patterns between the two groups were not significant. Ground-glass opacity (51.9% vs. 33.3%, p = 0.11) and pleural effusion (29.6% vs. 13.7%, p = 0.09) tended to be more common in the RV group.

Fig. 2 shows the monthly distribution of RV and IFV cases over 48 months. RV-associated pneumonia occurred sporadically throughout the year whereas IFV-associated pneumonia occurred predominately from December to March.
### Table 3
Identity of co-pathogens in patients with severe human rhinovirus- and influenza virus-associated pneumonia.

| Co-pathogens* | Total (n = 78) | Rhinovirus (n = 27) | Influenza virus (n = 51) | p-Value |
|---------------|----------------|---------------------|-------------------------|---------|
| Any           | 38 (48.7)      | 12 (44.4)           | 26 (51.0)               | 0.58    |
| Other virus   | 14 (17.9)      | 8 (29.6)            | 6 (11.8)                | 0.07    |
| Respiratory syncytial virus | 6  | 2<sup>+</sup> | 4 | |
| Cytomegalovirus | 4  | 4<sup>+</sup> | 0 | |
| Human coronavirus<sup>1</sup> | 4  | 3<sup>+</sup> | 3 | |
| Parainfluenza virus | 1  | 1<sup>+</sup> | 0 | |
| Bacteria      | 24 (30.8)      | 5 (18.5)            | 19 (37.3)               | 0.09    |
| S. aureus     | 7              | 0                   | 7                       | 0.09    |
| A. baumannii  | 5              | 2                   | 3<sup>+</sup>           |         |
| S. pneumoniae | 5              | 2                   | 3                       |         |
| P. aeruginosa | 2              | 0                   | 2<sup>+</sup>           |         |
| K. pneumoniae | 2              | 0                   | 2                       |         |
| S. pyogenes   | 1              | 0                   | 1                       |         |
| C. striatum   | 1              | 0                   | 1                       |         |
| E. cloacae    | 1              | 1                   | 0                       |         |
| C. freundii   | 1              | 0                   | 1                       |         |
| Non-tuberculous mycobacteria, unspecified | 1 | 0 | 1 | |
| Aspergillus species | 6 (7.7) | 2 (7.4) | 4 (7.8) | 1.00 |
| Pneumocystis jirovecii | 4 (5.1) | 4 (14.8) | 0 | 0.01 |

<sup>a</sup> Include pathogens identified from BAL fluid specimen or other specimens including nasopharyngeal specimen, sputum, endotracheal aspirate, and blood culture.

<sup>b</sup> Respiratory syncytial virus A and human coronavirus 229E/NL63 were identified together.

<sup>c</sup> Include two human coronavirus OC43/HKU-1 and two human coronavirus 229E/NL63.

<sup>d</sup> PIV-1 and PIV-3 were co-identified.

<sup>+</sup> In one patient, P. aeruginosa and A. baumannii were co-identified.

### Table 4
Clinical, laboratory, and radiologic characteristics of patients with severe human rhinovirus-associated pneumonia and severe influenza virus-associated pneumonia.

|                         | Total (n = 78) | Rhinovirus (n = 27) | Influenza virus (n = 51) | p-Value |
|-------------------------|----------------|---------------------|-------------------------|---------|
| Dyspnea                 | 73 (93.6)      | 27 (100)            | 46 (90.2)               | 0.16    |
| Sputum                  | 63 (80.8)      | 21 (77.8)           | 42 (82.4)               | 0.63    |
| Fever > 38 °C           | 62 (79.5)      | 19 (70.4)           | 43 (84.3)               | 0.15    |
| Cough                   | 61 (78.2)      | 18 (66.7)           | 43 (84.3)               | 0.07    |
| Altered mentality       | 18 (23.1)      | 6 (22.2)            | 12 (23.5)               | 0.90    |
| Diarrhea                | 5 (6.4)        | 3 (11.1)            | 2 (3.9)                 | 0.33    |
| Septic shock at ICU admission | 36 (46.2) | 8 (29.6) | 28 (54.9) | 0.03 |
| Mechanical ventilation  | 75 (96.2)      | 26 (96.3)           | 49 (96.1)               | 1.00    |
| APACHE II score (mean ± SD) | 24.4 ± 6.4 | 25.6 ± 6.9 | 23.7 ± 6.0 | 0.23 |
| SOFA score (median, IQR) | 10.0 (7.0–12.5) | 10.0 (7.3–12.0) | 10.0 (6.0–13.0) | 0.82 |
| Laboratory findings (median, IQR) | | | | |
| White blood cells/mm<sup>3</sup> | 9500 (4400–15,150) | 9400 (5100–15,800) | 9600 (4100–15,000) | 0.85 |
| Platelets, 10<sup>3</sup>/mm<sup>3</sup> | 146 (82–212) | 154 (83–219) | 136 (77–206) | 0.63 |
| C-reactive protein, mg/dl | 13.4 (6.1–20.8) | 13.4 (6.9–19.6) | 11.4 (5.7–23.2) | 0.99 |
| Procalcitonin, ng/ml | 1.5 (0.2–10.0) | 1.9 (0.2–24.4) | 1.1 (0.2–5.4) | 0.40 |
| BAL fluid cellular analysis (median, IQR) | | | | |
| Total WBC count, cell/μL | 280 (135–1330) | 210 (100–930) | 500 (180–1790) | 0.17 |
| Neutrophils, % | 77.0 (39.3–88.8) | 76.0 (39.5–87.5) | 80.0 (38.0–89.0) | 0.95 |
| Lymphocytes, % | 6.0 (2.0–15.8) | 6.0 (2.5–14.0) | 6.0 (2.0–21.0) | 0.89 |
| Macrophages, % | 15.5 (6.3–41.0) | 17.0 (6.0–39.5) | 14.0 (6.0–45.0) | 0.92 |
| Radiologic findings | | | | |
| Bilateral involvement | 74 (94.9) | 25 (92.6) | 49 (96.1) | 0.61 |
| Diffuse involvement | 46 (59.0) | 16 (59.3) | 30 (58.8) | 0.97 |
| Dominant pattern | | | | |
| Peribronchial pattern | 36 (46.2) | 12 (44.4) | 24 (47.1) | | |
| Interstitial pattern | 21 (26.9) | 10 (37.0) | 11 (21.6) | | |
| Lobar pattern | 19 (24.4) | 5 (18.5) | 14 (27.5) | | |
| Other | 2 (2.6) | 0 | 2 (3.9) | | |
| Ground-glass opacity | 31 (39.7) | 14 (51.9) | 17 (33.3) | 0.11 |
| Pleural effusion | 15 (19.2) | 8 (29.6) | 7 (13.7) | 0.09 |
| Nodule | 11 (14.1) | 3 (11.1) | 8 (15.7) | 0.74 |

Data are presented as No. (%) unless otherwise stated.

APACHE, acute physiology and chronic health evaluation; BAL, bronchoalveolar lavage; ICU, intensive care unit; IQR, interquartile range; SD, standard deviation; SOFA, sequential organ failure assessment; WBC, white blood cell count.
4.5. Outcomes

Table 5 summarizes the comparisons of outcomes between the two groups. Median length of ICU stay and the proportion of patients complicated by ventilator-associated pneumonia were similar between the two groups. The 28-day mortality, ICU mortality, and in-hospital mortality were not significantly different between groups. The presence of bacterial coinfection was not associated with increased in-hospital mortality in either the RV group (bacterial coinfection, 60.0% vs. no bacterial coinfection, 54.5%, \( p = 1.00 \)) or the IFV group (bacterial coinfection, 47.4% vs. no bacterial coinfection, 53.1%, \( p = 0.69 \)).

|                          | Total (n = 78) | Rhinovirus (n = 27) | Influenza virus (n = 51) | p-Value |
|--------------------------|---------------|---------------------|--------------------------|---------|
| ICU stay, day (median, IQR) | 13.0 (6.0–27.0) | 13.0 (8.0–30.0) | 13.0 (5.0–27.0) | 0.55    |
| Complicated by ventilator-associated pneumonia | 18 (23.1) | 5 (18.5) | 13 (25.5) | 0.49    |
| Mortality                |               |                     |                          |         |
| 7-day mortality           | 7 (9.0)       | 2 (7.4)             | 5 (9.8)                  | 1.00    |
| 14-day mortality          | 16 (20.5)     | 6 (22.2)            | 10 (19.6)               | 0.79    |
| 21-day mortality          | 21 (26.9)     | 6 (22.2)            | 15 (29.4)               | 0.50    |
| 28-day mortality          | 26 (33.3)     | 8 (29.6)            | 18 (35.3)               | 0.61    |
| 60-day mortality          | 38 (48.7)     | 14 (51.9)           | 24 (47.1)               | 0.69    |
| ICU mortality             | 35 (44.9)     | 13 (48.1)           | 22 (43.1)               | 0.67    |
| In-hospital mortality     | 41 (52.6)     | 15 (55.6)           | 26 (51.0)               | 0.70    |

ICU, intensive care unit; IQR, interquartile range.

5. Discussion

This study compared the clinical characteristics and outcomes of severe RV-associated pneumonia with those of severe IFV-associated pneumonia. RV-associated pneumonia was commonly associated with an immunocompromised state although about 20% of the RV patients were not immunocompromised. Additionally, the RV-associated patients tended to have more viral coinfections and fewer bacterial coinfections. Despite fewer cases of septic shock at the time of ICU admission in RV-associated pneumonia, clinical and laboratory features and outcomes did not differ between the groups.

A limited number of adult RV-associated pneumonia cases identified by bronchoscopic BAL have been reported previously [10,12,16–20]. The main characteristics of these cases are summarized in supplementary Table 1. All of the prior reports included small number of cases, most of which, with the exception of a report from a tertiary care hospital in U.S.A [10], occurred in severely immunocompromised patients. This group retrospectively reviewed clinical features of 20 patients (including three children) who had RV culture from their BAL over a 10-year period. Twelve (60.0%) needed mechanical ventilation. In-hospital mortality was relatively low (25.0%), which may be due to the lower frequency of severe immunocompromised conditions, such as hematopoietic stem cell transplant, in their patients. Notably, our study included five non-immunocompromised patients, two of which had underlying COPD and one who had undergone recent surgery. Another two elderly patients had no underlying illness or identifiable co-pathogen, suggesting that RV may be the sole cause of severe pneumonia in non-immunocompromised elderly patients.

Bacterial coinfection is a well-known complication of severe or fatal IFV infection, with reported rates of 18–55% [28]. The two most common bacterial co-pathogens, *S. aureus* and *S. pneumoniae*, are common colonizers of the nasopharynx [29–31]. In the present study, bacterial coinfection tended to be less frequent in the RV group than in the IFV group, and *S. aureus* was exclusively identified in the IFV group. Bacterial coinfection in influenza infection is likely caused by IFV propagation along the respiratory tree, together with mucociliary clearance impairment and IFV-induced respiratory tract epithelial cell damage [28]. By contrast, RVs involve only a small proportion of epithelial cells in the upper [32] and lower airway epithelium [7]. Therefore, the lower frequency of bacterial coinfection and septic shock may be due to the reduced extent of epithelial damage with RV infection. Since our study used different inclusion criteria for the two groups and included only patients with severe pneumonia admitted to medical ICU, the difference in the bacterial coinfection rate between the groups may have been biased. The proportion of individuals admitted to the ICU because of secondary bacterial pneumonia rather than viral pneumonia may be higher in the IFV group. Bacterial coinfection is a key cause of death in 20th century influenza pandemics [29,30], and bacterial coinfection was also associated with an increased risk of death in 2009 pandemic influenza A/H1N1 (pH1N1) [31,33]. In our results, however, bacterial coinfection was not associated with poorer outcomes in either IFV group or RV group, although the small numbers in our group may limit the generalizability of our findings and warrant further investigation.

Although cough tended to occur more frequently in the IFV group, other respiratory symptoms, laboratory findings, and radiographic findings were indistinguishable between the two groups. Recently, a U.S. group compared the characteristics between 2009 pH1N1 and other respiratory viruses in patients hospitalized with respiratory illness [34] and found that the presence of fever, cough, and gastrointestinal symptoms increased the likelihood of pH1N1 almost 10-fold in the pediatric population. Our study was limited to severe pneumonia patients admitted to the ICU, and more than two-thirds of both groups had respiratory symptoms. Therefore, a symptom-based approach is likely not reliable in differentiating clinical diagnoses among adult patients with severe pneumonia. The seasonal distribution of each respiratory virus and the temporal occurrence of respiratory viral illness in the community may help predict viral pathogens. Nevertheless, PCR tests for respiratory viruses are reliable and should be included for etiological diagnosis in patients with severe pneumonia.

Although septic shock at the time of initial presentation was less common in the RV group than in the IFV group, it was significantly associated with bacterial coinfection. Therefore, the presence of bacterial coinfections may be responsible for more severe manifestations of pneumonia at the time of ICU admission. Nevertheless, mortalities of patients were similarly high in both groups, likely reflecting the more frequent presence of immunocompromised conditions in the RV group. Taken together, our data suggest that host factor is an important contributor to the development of severe RV-associated pneumonia and affects the outcome.

Our study has several limitations. First, protected specimen brushing was not used during the study period, meaning BAL fluid may have been contaminated by upper airway secretions during...
the bronchoscopic procedure. Second, even in BAL fluid CV PCR-positive cases, RVs might be present as non-pathogenic colonizers. Third, because we did not perform a molecular study for serogrouping and serotyping, the impact of RV species and strains could not be evaluated. Finally, the RV group only included PCR-positive cases from BAL fluid, whereas the IFV group also included PCR-positive cases from nasopharyngeal specimens, indicating a possibility for biases associated with these different inclusion criteria.

In conclusion, severe RV-associated pneumonia patients were more likely to be immunocompromised and less likely to have bacterial coinfection and septic shock compared with patients who had severe IFV-associated pneumonia. However, both groups of pneumonia showed similar clinical and laboratory features and were associated with comparably high mortalities. Since our current study used different inclusion criteria for the two groups and included only severe pneumonia patients admitted to an ICU, further investigations are warranted.

Funding

This study was supported by grant 2012-389 from the Asan Institute of Life Sciences, Seoul, Republic of Korea.

Competing interests

The authors declare that there are no conflicts of interest to disclose.

Ethical approval

The study was approved by the Institutional Review Board of Asan Medical Center, Seoul, Korea (2010-0079).

Appendix A. Supplementary data

Supplementary data associated with this article can be found, in the online version, at http://dx.doi.org/10.1016/j.jcv.2014.11.010.

References

[1] Jacobs SE, Lamson DM, St George K, Walsh TJ. Human rhinoviruses. Clin Microbiol Rev 2013;26:135–62.
[2] Minor TE, Dick EC, Baker JW, Ouellette JJ, Cohen M, Reed CE. Rhinovirus and influenza type A infections as precipitants of asthma. Am Rev Respir Dis 1976;113:149–53.
[3] Greenberg SB, Allen M, Wilson J, Atmar RL. Respiratory viral infections in adults with and without chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2000;162:167–73.
[4] Genn JE, Galagan DM, Jarjour NN, Dick EC, Busse WW. Detection of rhinovirus RNA in lower airway cells during experimentally induced infection. Am J Respir Crit Care Med 1997;155:119–61.
[5] Papadopoulos NG, Sanderson G, Hunter J, Johnston SL. Rhinoviruses replicate effectively at lower airway temperatures. J Med Virol 1999;58:100–4.
[6] Papadopoulos NG, Bates PJ, Bardin PG, Papi A, Leis SH, Fraenkel DJ, et al. Rhinoviruses infect the lower airways. J Infect Dis 2000;181:1875–84.
[7] Mosser AG, Brockman-Schneider R, Aminova S, Burchell L, Sedgwick JB, Busse WW, et al. Similar frequency of rhinovirus-infected cells in upper and lower airway epithelium. J Infect Dis 2002;185:734–43.
[8] Nicholson KG, Kent J, Hammersley V, Cancio E. Risk factors for lower respiratory complications of rhinovirus infections in elderly people living in the community: prospective cohort study. BMJ 1996;313:1119–23.
[9] El-Sahly HM, Atmar RL, Glezen WP, Greenberg SB. Spectrum of clinical illness in hospitalized patients with common cold virus infections. Clin Infect Dis 2000;31:96–100.
[10] Malcolm E, Arruda E, Hayden FG, Kaiser L. Clinical features of patients with acute respiratory illness and rhinovirus in their bronchoalveolar lavages. J Clin Virol: the Off Publ Pan Am Soc Clin Virol 2001;21:9–16.
[11] Falsey AR, Walsh EE, Hayden FG. Rhinovirus and coronavirus infection-associated hospitalizations among older adults. J Infect Dis 2002;185:1338–41.
[12] Ison MG, Hayden FG, Kaiser L, Corey L, Boecht M. Rhinovirus infections in hematopoietic stem cell transplant recipients with pneumonia. Clin Infect Dis 2003;36:1139–43.
[13] Bardin PG, Fraenkel DJ, Sanderson G, Lampe F, Holgate ST. Lower airways inflammatory response during rhinovirus colds. Int Arch Allergy Immunol 1995;107:127–9.
[14] Johnston SL. Natural and experimental rhinovirus infections of the lower respiratory tract. Am J Respir Crit Care Med 1995;152:S46–52.
[15] Fraenkel DJ, Bardin PG, Sanderson G, Lampe F, Johnston SL, Holgate ST. Lower airways inflammation during rhinovirus colds in normal and in asthmatic subjects. Am J Respir Crit Care Med 1995;152:E115–20.
[16] Connelly Jr MG, Baughman RP, Dohn MN, Linnemann Jr CC. Recovery of viruses other than cytomegalovirus from bronchoalveolar lavage fluid. Chest 1980;85:1775–81.
[17] Carbino J, Gerbase MW, Wunderli W, Kolarova L, Nicod LP, Rochat T, et al. Respiratory viruses and severe lower respiratory tract complications in hospitalized patients. Chest 2004;125:1031–9.
[18] Ghosh S, Chaplin R, Couch R, Englund J, Raad I, Malik S, et al. Rhinovirus infections in myelosuppressed adult blood and marrow transplant recipients. Clin Infect Dis 1999;29:528–32.
[19] Gutmans JA, Peck AJ, Kuypers J, Boecht M. Rhinovirus as a cause of fatal lower respiratory tract infection in adult stem cell transplantation patients: a report of two cases. Bone Marrow Transplantation 2007;40:809–11.
[20] Bowden RA. Respiratory virus infections after marrow transplant: the Fred Hutchinson Cancer Research Center experience. Am J Med 1997;102:27–30, discussion 42–3.
[21] Choi SH, Hong SB, Ko GB, Lee Y, Park HJ, Park SY, et al. Viral infection in patients with severe pneumonia requiring intensive care unit admission. Am J Respir Crit Care Med 2012;186:325–32.
[22] Hong HL, Hong SB, Ko GB, Huh JW, Sung H, Do KH, et al. Viral infection is not uncommon in adult patients with severe hospital-acquired pneumonia. PLoS One 2014;9:e95805.
[23] Choi SH, Hong SB, Hong HL, Kim SH, Huh JW, Sung H, et al. Usefulness of cellular analysis of bronchoalveolar lavage fluid for predicting the etiology of pneumonia in critically ill patients. PLoS One 2014;9:e97346.
[24] Carratala J, Mykietiuk A, Fernandez-Sabe N, Suarez C, Dorca J, Verdaguer R, et al. Health care–associated pneumonia in hospital admission: epidemiology, antibiotic therapy, and clinical outcomes. Arch Intern Med 2007;167:1391–9.
[25] Mandell LA, Wunderink RG, Anzueto A, Bartlett JG, Campbell GD, Dean NC, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007;44(Suppl 2):S27–72.
[26] Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 2005;171:388–416.
[27] Micek ST, Kollef KE, Reichley RM, Roubinian N, Kollef MH. Health care–associated pneumonia and community-acquired pneumonia: a single-center experience. Antimicrob Agents Chemother 2007;51:3568–73.
[28] Chertow DS, Memoli MJ. Bacterial coinfection in influenza: a grand rounds review. JAMA 2013;309:275–82.
[29] Morens DM, Taubenberger JK, Fauci AS. Predominant role of bacterial pneumonia as a cause of death in pandemic influenza: implications for pandemic influenza preparedness. J Infect Dis 2008;198:962–70.
[30] Schwarzmann SW, Adler J, Sullivan BJ Jr, Marine WM. Bacterial pneumonia during the Hong Kong influenza epidemic of 1968–1969. Arch Intern Med 1971;127:1037–41.
[31] Race TW, Rubinson L, Uyeki TM, Vaughan FL, John BB, Miller 3rd RR, et al. Critical illness from 2009 pandemic influenza A virus and bacterial coinfection in the United States. Crit Care Med 2012;40:1487–98.
[32] Arruda E, Boyle TR, Winther B, Pevear DC, Gwaltney Jr JM, Hayden FG. Localization of human rhinovirus replication in the upper respiratory tract by in situ hybridization. J Infect Dis 1995;171:1329–33.
[33] Palacios G, Horning M, Cisterna D, Savji N, Bussetti AV, Kapoor V, et al. Streptococcus pneumoniae coinfection is correlated with the severity of H1N1 pandemic influenza. PLoS One 2009;4:e8540.
[34] Chan PA, Mermel LA, Andrea SB, McCulloh R, Mills JP, Echenique I, et al. Distinguishing characteristics between pandemic 2009-2010 influenza A (H1N1) and other viruses in patients hospitalized with respiratory illness. PLoS One 2011;6:e24734.